Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Express Scripts
Dow
Baxter
Boehringer Ingelheim

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

Details for Patent: RE43298


Email this page to a colleague

« Back to Dashboard

Summary for Patent: RE43298
Title:Peptides as NS3-serine protease inhibitors of hepatitis C virus
Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
Inventor(s): Saksena; Anil K. (Upper Montclair, NJ), Girijavallabhan; Viyyoor Moopil (Parsippany, NJ), Lovey; Raymond G. (West Caldwell, NJ), Jao; Edwin (Warren, NJ), Bennett; Frank (Cranford, NJ), McCormick; Jinping L. (Edison, NJ), Wang; Haiyan (Cranbury, NJ), Pike; Russell E. (Stanhope, NJ), Bogen; Stephane L. (Somerset, NJ), Chan; Tin-Yau (Edison, NJ), Liu; Yi-Tsung (Morris Township, NJ), Zhu; Zhaoning (East Windsor, NJ), Njoroge; F. George (Warren, NJ), Arasappan; Ashok (Bridgewater, NJ), Parekh; Tejal (Mountain View, CA), Ganguly; Ashit K. (Upper Montclair, NJ), Chen; Kevin X. (Edison, NJ), Venkatraman; Srikanth (Fords, NJ), Vaccaro; Henry M. (South Plainfield, NJ), Pinto; Patrick A. (Morris Plains, NJ), Santhanam; Bama (Bridgewater, NJ), Kemp; Scott Jeffrey (San Diego, CA), Levy; Odile Esther (San Diego, CA), Lim-Wilby; Marguerita (Santa Fe, NM), Tamura; Susan Y. (Santa Fe, NM), Wu; Wanli (Edison, NJ), Hendrata; Siska (Edison, NJ), Huang; Yuhua (Scotch Plains, NJ)
Assignee: Schering Corporation (Kenilworth, NJ) Dendreon Corporation (San Diego, CA)
Application Number:13/068,159
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent RE43298

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme VICTRELIS boceprevir CAPSULE;ORAL 202258-001 May 13, 2011 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent RE43298

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 033985 ⤷  Free Forever Trial
Argentina 038183 ⤷  Free Forever Trial
Argentina 069373 ⤷  Free Forever Trial
Austria 461207 ⤷  Free Forever Trial
Austria 469914 ⤷  Free Forever Trial
Australia 2001276988 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
Express Scripts
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.